胡 蝶,张广玉

脂蛋白[Lp（a）]是一种由载脂蛋白（a）和低密度脂蛋白（LDL）样颗粒结合的特殊脂蛋白，主要受LPA基因调控。Lp（a）是动脉硬化斑块中主要脂质成分，是动脉粥样硬化的标志,其可能成为预防脑卒中发生的治疗靶点。目前的抗血脂治疗，如他汀类、贝特类和依折麦布等药物，对Lp（a）水平的疗效欠佳，本综述旨在总结Lp（a）的作用机制、与脑卒中发生发展的相关性及部分最新治疗，为LP（a）在脑血管病中的研究提供部分理论依据，以期延缓不良事件的发生，改善患者的预后。

脂蛋白a；缺血性脑卒中；治疗

[1] CHEN C Y,LIN P T,WANG Y H,et al.Etiology and risk factors of intracraial hemorrhage and ischemic stroke in young adults[J].J Chin Med Assoc,2021,84(10):930-936. [2] Milionis HJ,Winder AF,Mikhailidis DP.Lipoprotein(a)and stroke.J Clin Pathol.2000 Jul;53(7):487-96. [3] Borrelli MJ,Youssef A,Boffa MB,Koschinsky ML.New Frontiers in Lp(a)-Targeted Therapies.Trends Pharmacol Sci.2019 Mar;40(3):212-225. [4] Schmidt K,Noureen A,Kronenberg F,Utermann G.Structure,function,and genetics of lipoprotein(a).J Lipid Res.2016 Aug;57(8):1339-59. [5]秦敬翠,张志珺,孙鼎明.血清脂蛋白(a)与缺血性脑卒中关系的临床研究[J].中华脑血管病杂志(电子版),2009,3(2):76-80. [6] Hachinski V,GraVagnino C,Beaudry M,et al.Lipids and stroke:a paradox resolved.Arch Neurol 1996;53:303–8 [7] 刘航齐,贾玫.脂蛋白相关磷脂酶A2水解脂蛋白(a)连接的氧化磷脂促进动脉粥样硬化发生发展作用机制的研究进展[J].中华检验医学杂志,2018,41(11):897-900. [8] BERNICE W,SUNDSTROM J,ARNLOv J.Metabolic risk 6∞—tots for stroke and transient ischemie attacks in middle--aged inen.A community-based study with long-term follow-up[J].Stroke,2006｡37(18):2898—2913. [9] 0 Van Kooten F,van Krimpen J,Dippel DW,et al.Lipoprotein(a)in patients with acute cerebral ischemia.Stroke 1996;27:1231–5. [10] Nagayama M,Shinohara Y,Nagayama T.Lipoprotein(a)and ischemic cerebrovascular disease in young adults.Stroke 1994;25:74–8. [11] 秦敬翠,张志珺,孙鼎明.血清脂蛋白(a)与缺血性脑卒中关系的临床研究[J].中华脑血管病杂志(电子版),2009,3(2):76-80. [12] Wilson DP,Jacobson TA,Jones PH,et al.Use of Lipoprotein(a)in clinical practice:a biomarker whose time has come.A scientific statement from the National Lipid Association[J].J Clin Lipidol,2019,13(3):374-392. [13] Handhle A,Viljoen A,Wierzbicki AS.Elevated Lipoprotein(a):Background,Current Insights and Future Potential Therapies.Vasc Health Risk Manag.2021 Sep 7;17:527-542. [14] Gaudet D,Watts GF,Robinson JG,et al.Effect of alirocumab on lipoprotein(a)over≥1.5 years(from the phase 3 ODYSSEY program)[J].Am J Cardiol,2017,119(1):40-46 [15] Roeseler E,Julius U,Heigl F,et al.Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease:prospective 5 years of follow-up and apolipoprotein(a) characterization[J]. Arterioscler Thromb Vasc Biol,2016,36(9):2019-2027.

点击下载PDF